Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHikma Pharmaceuticals PLC ADR

Hikma Pharmaceuticals PLC ADR

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
43.285 USD -4.46 ( 9.35%)
Last update at 2026-11-10T16:29:00Z
VOLUME
2
Market Cap
4274.93M
P/E
11.74

Momentum Score

…

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
43.28
Low
43.28
High
52 Week Price Range
30.46
Low
47.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Hikma Pharmaceuticals is a multinational maker of generic medicines, branded products in the Middle East and North Africa, and hospital injectables. Long-term growth may be driven by scale in US generics and injectables, manufacturing capacity and expansion in emerging markets, making it attractive for investors seeking a diversified pharmaceutical manufacturer with established production capabilities.
Principal risks are sustained pricing and competition in generics, regulatory and manufacturing compliance issues, and geopolitical and currency exposure in key markets.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
47.75
Dividend Yield
4.16%
Revenue TTM
3419.00M
Revenue Per Share
31.27
Gross Profit TTM
1506.00M
Debt / Equity
0.62
ROE
15.41%
Net Debt
1276.00M
ROCE
13.50%
Diluted EPS TTM
3.52

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 520.21M 454.00M 281.00M 233.00M 544.00M
Minority interest -5.00M -3.00M -2.00M -3.00M 1.00M
Net income 402.94M 359.00M 190.00M 188.00M 421.00M
Selling general administrative 566.00M 568.00M 638.00M 509.00M 488.00M
Selling and marketing expenses - - 88.00M - -
Gross profit 1441.00M 1415.00M 1407.00M 1238.00M 1301.00M
Reconciled depreciation 238.00M 197.00M 259.00M 193.00M 145.00M
Ebit 569.33M 530.00M 368.00M 507.00M 582.00M
Ebitda 781.82M 727.00M 559.00M 700.00M 735.00M
Depreciation and amortization 212.50M 197.00M 191.00M 193.00M 153.00M
Operating income 569.33M 612.00M 367.00M 507.00M 582.00M
Other operating expenses 2787.50M 2515.00M 2508.00M 2035.00M 1994.00M
Interest expense 106.25M 88.00M 87.00M 77.00M 69.00M
Tax provision 112.00M 93.00M 89.00M 42.00M 124.00M
Interest income 6.00M 8.00M 7.00M 3.00M 30.00M
Net interest income -91.00M -80.00M -83.00M -52.00M -39.00M
Income tax expense 112.26M 93.00M 89.00M 42.00M 124.00M
Total revenue 3356.83M 3127.00M 2875.00M 2517.00M 2553.00M
Total operating expenses 808.00M 803.00M 1040.00M 756.00M 742.00M
Cost of revenue 1908.00M 1712.00M 1468.00M 1279.00M 1252.00M
Total other income expense net -49.11M -158.00M -86.00M -274.00M -38.00M
Net income from continuing ops 407.00M 362.00M 192.00M 191.00M 420.00M
Net income applicable to common shares - - - 188.00M 421.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5671.00M 5133.00M 4680.00M 4471.00M 4372.00M
Intangible assets 777.00M 774.00M 712.00M 735.00M 607.00M
Other current assets 104.00M 159.00M 107.00M 110.00M 97.00M
Total liab 3065.00M 2812.00M 2471.00M 2323.00M 1905.00M
Total stockholder equity 2593.00M 2310.00M 2198.00M 2135.00M 2453.00M
Other current liab 417.00M 889.00M 795.00M 638.00M 339.00M
Common stock 40.00M 40.00M 40.00M 40.00M 42.00M
Capital stock 40.00M 40.00M 40.00M 40.00M 42.00M
Retained earnings 2556.00M 2362.00M 2158.00M 2092.00M 2189.00M
Other liab - - - 111.00M 164.00M
Good will 393.00M 382.00M 388.00M 389.00M 285.00M
Other assets - - - 215.00M 194.00M
Cash 328.00M 188.00M 205.00M 270.00M 426.00M
Total current liabilities 1453.00M 1978.00M 1339.00M 1077.00M 1016.00M
Current deferred revenue 207.00M - 179.00M - 294.00M
Net debt 1276.00M 1118.00M 986.00M 1013.00M 420.00M
Short term debt 114.00M 653.00M 161.00M 148.00M 121.00M
Short long term debt 106.00M 642.00M 150.00M 139.00M 112.00M
Short long term debt total 1604.00M 1306.00M 1191.00M 1283.00M 846.00M
Other stockholder equity 282.00M 245.00M 282.00M 3.00M 222.00M
Property plant equipment - - - 1081.00M 1146.00M
Total current assets 2643.00M 2263.00M 2100.00M 1999.00M 2094.00M
Net tangible assets - - - 1011.00M 1561.00M
Short term investments 26.00M 25.00M 24.00M 22.00M 24.00M
Net receivables 1079.00M 905.00M 873.00M 843.00M 876.00M
Long term debt 1445.00M 607.00M 975.00M 1074.00M 651.00M
Inventory 1106.00M 986.00M 891.00M 776.00M 695.00M
Accounts payable 715.00M 358.00M 309.00M 291.00M 262.00M
Accumulated other comprehensive income -285.00M -337.00M -282.00M - -
Non currrent assets other 92.00M 44.00M 38.00M 22.00M 24.00M
Non current assets total 3028.00M 2870.00M 2580.00M 2472.00M 2278.00M
Capital lease obligations 53.00M 57.00M 66.00M 70.00M 83.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.00M -381.00M -333.00M -607.00M 3.00M
Change to liabilities - - - 16.00M 14.00M
Total cashflows from investing activities -394.92M -381.00M -333.00M -607.00M -238.00M
Net borrowings 301.00M 124.00M -93.00M 447.00M -114.00M
Total cash from financing activities 58.14M -188.00M -337.00M -58.00M -287.00M
Change to operating activities - - - -49.00M 84.00M
Net income 402.94M 455.00M 281.00M 233.00M 544.00M
Change in cash 140.00M -17.00M -65.00M -156.00M 103.00M
Begin period cash flow 188.00M 205.00M 270.00M 426.00M 323.00M
End period cash flow 328.00M 188.00M 205.00M 270.00M 426.00M
Total cash from operating activities 359.84M 564.00M 608.00M 530.00M 638.00M
Issuance of capital stock -36.00M -38.00M 0.00M - -
Depreciation 238.00M 197.00M 198.00M 193.00M 145.00M
Other cashflows from investing activities 1.00M -52.00M -33.00M -3.00M -12.00M
Dividends paid 185.43M 175.00M 137.00M -125.00M -120.00M
Change to inventory -86.20M -112.00M -115.00M -102.00M 38.00M
Change to account receivables -97.23M -144.00M -24.00M 4.00M -166.00M
Sale purchase of stock -36.08M - 0.00M -300.00M -
Other cashflows from financing activities -22.05M -99.00M -107.00M 1692.00M 309.00M
Change to netincome - - - 283.00M 67.00M
Capital expenditures 197.46M 235.00M 204.00M 225.00M 229.00M
Change in working capital -250.58M -135.00M 80.00M -131.00M -30.00M
Stock based compensation 23.00M 27.00M 25.00M 22.00M 29.00M
Other non cash items -53.52M 20.00M 24.00M 213.00M 39.00M
Free cash flow 162.38M 329.00M 404.00M 305.00M 409.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HKMPY
Hikma Pharmaceuticals PLC ADR		 -4.46
9.35%		 43.28 11.74 8.10 1.25 1.69 1.76 6.97
MKKGY
Merck KGaA ADR		 -0.04
0.12%		 33.67 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -0.58
0.34%		 169.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.16
0.76%		 20.93 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 42.77 - 10.66 0.01 1.16 2.94 23.11

Profile*

Hikma Pharmaceuticals PLC ADR

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

10 Portman Square, London, United Kingdom, W1H 6AZ

44 20 7399 2760

https://www.hikma.com

9500

Name Title Year Born
Engineer Said Samih Taleb Darwazah Exec. Chairman & CEO 1957
Mr. Mazen Samih Taleb Darwazah Exec. Vice Chairman & Pres of MENA 1958
Mr. Khalid Waleed Hosny Al Nabilsi Chief Financial Officer 1972
Mr. Hussein Arkhagha Company Sec. & Chief Counsel NA
Mr. Bassam Wael Rushdi Kanaan CFA, CPA Exec. VP of Corp. Devel. and M&A 1965
Ms. Susan Ringdal Exec. VP of Strategic Planning & Global Affairs NA
Ms. Majda Labadi Exec. VP of Organisational Devel. NA
Mr. Riad Mishlawi Pres of Injectables NA
Mr. Brian Hoffmann Pres of Generics NA
Mr. Samuel Park Global Head of Intellectual Property (IP) & Gen. Counsel for US NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…